Kabra Drugs lands ₹200 cr LOI from Chhattisgarh for pharma plant
The nano-cap pharma firm received a letter of intent from the state government for a facility at Nava Raipur Pharma Park, an investment worth over 3.5 times its market cap.
— 2 earlier stories on Kabra Drugs Ltd. →What's new
- Received LOI from Chhattisgarh for ₹200 cr pharma plant at Nava Raipur Pharma Park.
- Project expected to create approximately 250 direct and indirect jobs.
- Non-binding, subject to definitive agreements and approvals.
Why this matters
For a nano-cap with just ₹55 cr market cap, a ₹200 cr investment is an over 3.5 times bet on scale. It could push revenue far beyond the ₹92.74 cr achieved in FY26. State backing adds credibility, but the LOI is non-binding. Execution, including financing and approvals, remains the open question.
What we're watching
- Execution of definitive agreements and receipt of state incentives.
- How the company plans to finance a capex over 3.5 times its market cap.
- Timeline for construction and revenue contribution from the new facility.
The full read
Kabra Drugs went from zero revenue to ₹92.74 crore in a single year. Now it wants to do something far bigger. The company received a Letter of Intent from the Chhattisgarh government for a ₹200 crore pharmaceutical plant at Nava Raipur Pharma Park, an investment over 3.5 times its current market cap of ₹55 crore. The project would add around 250 jobs and expand manufacturing capacity drastically. But the LOI is non-binding. The real test is whether a nano-cap with ₹0.02 debt-to-equity and a P/E of 11.1 can secure financing and clear state approvals. If it does, Kabra could quintuple its scale. If not, the stock has already priced in a moonshot.
Questions answered
- How does a ₹200 cr investment compare to Kabra Drugs' current size?
- The proposed investment is over 3.5 times the company's market cap of ₹55 crore and more than double its FY26 revenue of ₹92.74 crore if realized.
- What makes this LOI credible given the company's nano-cap status?
- The counterparty is the Government of Chhattisgarh, adding credibility. However, the LOI is non-binding and subject to definitive agreements and approvals.
- What are the key milestones before this project becomes reality?
- The company must sign definitive agreements, obtain necessary approvals from the state government, and secure the promised incentives.
- How does this fit with Kabra Drugs' recent growth trajectory?
- Kabra Drugs jumped from zero revenue in FY25 to ₹92.74 cr in FY26. This LOI could propel it to a much larger scale if executed.
- Is there any financial risk for investors at this stage?
- Yes, the stock may have priced in the LOI already. Until definitive agreements are signed, the project could fall through, and the company would still need to arrange financing for a capex far exceeding its market cap.
Story so far
All notes on KABRADG →- 13 Jun 2026 · 3:57 PM IST Kabra Drugs lands ₹200 cr LOI from Chhattisgarh for pharma plant
- 15d ago Kabra Drugs goes from zero revenue to ₹92.74 cr in one year
- 15d ago Kabra Drugs' revenue jumped from zero to ₹92.74 cr in a single year